The price of innovation: new estimates of drug development costs
Article Abstract:
The data, which is obtained from a survey on the research and development costs of 68 randomly selected new drugs from 10 pharmaceutical firms, is used to estimate the average pre-tax cost of new drug development. The estimated average out-of-pocket cost per new drug is US$ 403 million, but for market approval at a discount rate of 11% yields a total pre-approval cost estimate of US$ 802 million.
Publication Name: Journal of Health Economics
Subject: Health care industry
ISSN: 0167-6296
Year: 2003
User Contributions:
Comment about this article or add new information about this topic:
Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research
Article Abstract:
Research into the success of large firms to develop new pharmaceuticals is given. The research shows that large firms superior performance is driven by scope rather than scale.
Publication Name: Journal of Health Economics
Subject: Health care industry
ISSN: 0167-6296
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Cost implications of regionalizing open heart surgery units. Clinical and socioeconomic determinants of health care use among HIV-infected patients in the Department of Veterans Affairs
- Abstracts: Dimensions of Patient Empowerment: Implications for Professional Services Marketing. Factors Influencing Employee Health Plan Choice in the Corporate Setting
- Abstracts: Health care is an individual necessity and a national luxury: applying multilevel decision models to the analysis of health care expenditures
- Abstracts: Comparative dynamic analysis of the full Grossman model. Alternative approaches to valuing intangible health losses: the evidence for multiple sclerosis
- Abstracts: Is health care really a luxury? The determinants of health care expenditure: a cointegration approach